PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast - Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

12/21/23 • 23 min

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EGP865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024.

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Previous Episode

W. Troy Donahoo, MD, FTOS - Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PZM865. CME/NCPD/AAPA credit will be available until November 26, 2024.

Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Lilly.

Disclosures
W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity.

Amy J. Sheer, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Actors of Health Care Theatre have nothing to disclose.

Medical Directors
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Next Episode

undefined - PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape

PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.

Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
PD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.
Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.

Co-Chair/Planner
Jonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.